FINASTERIDE tablet, film coated

البلد: الولايات المتحدة

اللغة: الإنجليزية

المصدر: NLM (National Library of Medicine)

العنصر النشط:

FINASTERIDE (UNII: 57GNO57U7G) (FINASTERIDE - UNII:57GNO57U7G)

متاح من:

Thirty Madison Inc

طريقة التعاطي:

ORAL

نوع الوصفة الطبية :

PRESCRIPTION DRUG

الخصائص العلاجية:

Finasteride tablets are indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY . Efficacy in bitemporal recession has not been established. Finasteride tablets are not indicated for use in women. Finasteride is contraindicated in the following: - Pregnancy. Finasteride use is contraindicated in women when they are or may potentially be pregnant. Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. [See Warnings and Precautions (5.1),

ملخص المنتج:

Finasteride tablets, USP 1 mg: reddish brown, 7 mm, round, biconvex, film coated tablets, marked ‘F1’ on one side and plain on other side. They are supplied as follows: NDC  71713-096-90 Bottle of 90 (with desiccant). Storage and Handling Store at 20º to 25 ºC (68 º to 77 ºF) [See USP controlled room temperature]. Keep container closed and protect from moisture. Women should not handle crushed or broken finasteride tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. Finasteride tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets are not broken or crushed [see Warnings and Precautions (5.1), Use in Specific Populations (8.1) and Patient Counseling Information (17.1)] .

الوضع إذن:

Abbreviated New Drug Application

خصائص المنتج

FINASTERIDE- FINASTERIDE TABLET, FILM COATED
THIRTY MADISON INC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
FINASTERIDE TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
FINASTERIDE TABLETS.
FINASTERIDE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1992
INDICATIONS AND USAGE
Finasteride is a 5α-reductase inhibitor indicated for the treatment
of male pattern hair loss
(androgenetic alopecia) in MEN ONLY ( 1).
Finasteride tablets are not indicated for use in women ( 1, 4, 5.1).
DOSAGE AND ADMINISTRATION
Finasteride tablets may be administered with or without meals ( 2).
One tablet (1 mg) taken once daily ( 2).
In general, daily use for three months or more is necessary before
benefit is observed ( 2).
DOSAGE FORMS AND STRENGTHS
1 mg tablets ( 3).
CONTRAINDICATIONS
Pregnancy ( 4, 5.1, 8.1, 16).
Hypersensitivity to any components of this product ( 4).
WARNINGS AND PRECAUTIONS
Finasteride is not indicated for use in women or pediatric patients (
5.1, 5.4).
Women should not handle crushed or broken finasteride tablets when
they are pregnant or may
potentially be pregnant due to potential risk to a male fetus ( 5.1,
8.1, 16).
Finasteride causes a decrease in serum PSA levels. Any confirmed
increase in PSA while on finasteride
may signal the presence of prostate cancer and should be evaluated,
even if those values are still
within the normal range for men not taking a 5α-reductase inhibitor (
5.2).
5α-reductase inhibitors may increase the risk of high-grade prostate
cancer ( 5.3, 6.1).
ADVERSE REACTIONS
The most common adverse reactions, reported in ≥1% of patients
treated with finasteride and greater
than in patients treated with placebo are: decreased libido, erectile
dysfunction and ejaculation disorder (
6.1).
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ACCORD HEALTHCARE INC.
AT 1-866-941-
7875 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
SEE 17 FOR PATIENT COUNSELING INFORMATION AND FDA-APPROVED PATIENT
LABELING.
RE